Published in Nervenarzt on April 01, 2005
The ocular toxicity and pharmacokinetics of simvastatin following intravitreal injection in mice. Int J Ophthalmol (2017) 0.75
B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 6.88
Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell (1988) 5.73
T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature (1987) 3.96
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol (2011) 2.90
Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology (2002) 2.34
Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol (1990) 1.83
Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis. Neurology (2008) 1.78
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology (2008) 1.76
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology (2005) 1.56
Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.53
Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler (2011) 1.51
Involvement of distinct murine T-cell receptors in the autoimmune encephalitogenic response to nested epitopes of myelin basic protein. Proc Natl Acad Sci U S A (1988) 1.51
Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol (1988) 1.50
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition. J Exp Med (1985) 1.46
Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study. Eur J Neurol (2012) 1.45
The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol (2001) 1.43
[Myopathies under therapy with lipid-lowering agents]. Nervenarzt (2005) 1.40
Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain (2008) 1.37
Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc Natl Acad Sci U S A (1989) 1.36
Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. J Clin Invest (2001) 1.36
Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis. Curr Opin Neurol (1999) 1.35
Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain (2003) 1.12
Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler (2010) 1.11
Autosomal dominant juvenile amyotrophic lateral sclerosis and distal hereditary motor neuronopathy with pyramidal tract signs: synonyms for the same disorder? Brain (2002) 1.09
The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol (2000) 1.07
Th17 Cells in MS and Experimental Autoimmune Encephalomyelitis. Int MS J (2009) 1.06
A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology (2011) 1.05
Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J Immunol (1998) 1.05
Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control. Neurology (2012) 1.04
Response to the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, and activated macrophages. J Natl Cancer Inst (1980) 1.03
Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation. Eur J Immunol (1995) 1.02
Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol (2012) 1.00
Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol (2014) 1.00
T cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: studies with TCR V beta 8.2 transgenic mice. J Exp Med (1994) 0.98
T cell specificity for class II (I-A) and the encephalitogenic N-terminal epitope of the autoantigen myelin basic protein. J Immunol (1987) 0.95
Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. Brain (1998) 0.93
Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol (2014) 0.91
[Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis]. Nervenarzt (2005) 0.91
Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology (2011) 0.91
Prion proteins: a biological role beyond prion diseases. Acta Neurol Scand (2007) 0.90
Polymorphic residues on the I-A beta chain modulate the stimulation of T cell clones specific for the N-terminal peptide of the autoantigen myelin basic protein. J Immunol (1989) 0.89
Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology (2009) 0.88
Expression and distribution of transcription factor NF-kappaB and inhibitor IkappaB in the inflamed peripheral nervous system. J Neuroimmunol (2001) 0.88
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol (2004) 0.88
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology (2012) 0.87
T cell activation status determines the cytokine pattern induced by zymosan and bacterial DNA both in thymocytes and splenocytes. Clin Exp Immunol (2013) 0.86
Progress in Guillain-Barré syndrome. Curr Opin Neurol (2001) 0.85
Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA). Genes Immun (2002) 0.85
Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets (2007) 0.85
Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies. Neurology (2007) 0.84
Leopold Ordenstein: on paralysis agitans and multiple sclerosis. Mult Scler (2007) 0.83
MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy. J Neurol Neurosurg Psychiatry (2003) 0.83
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol (2009) 0.83
Monomethylfumarate reduces in vitro migration of mononuclear cells. Neurol Sci (2014) 0.82
Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production. Int Immunol (1999) 0.82
Therapy of autoimmune diseases with antibody to immune response gene products or to T-cell surface markers. Ann N Y Acad Sci (1986) 0.82
Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler (2013) 0.82
Schwann cell-specific regulation of IL-1 and IL-1Ra during EAN: possible relevance for immune regulation at paranodal regions. J Neuroimmunol (2001) 0.82
Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years. Mult Scler (2005) 0.81
Statins and demyelination. Curr Top Microbiol Immunol (2008) 0.81
Highlights from the Fifth International Congress of the International Society of Neuroimmunology. J Neuroimmunol (1999) 0.81
Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Mult Scler (2011) 0.80
Spotlight on statins. Int MS J (2007) 0.80
A patient with a benign course of neuromyelitis optica (Devic's syndrome) over 12 years: MRI follow up and histological findings. J Neurol (2006) 0.80
TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leukoc Biol (2010) 0.80
Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol (2007) 0.80
Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results. Mult Scler (2007) 0.80
Polyclonal immunoglobulins (IVIg) induce expression of MMP-9 in microglia. J Neuroimmunol (2009) 0.79
Monoclonal antibodies in the therapy of multiple sclerosis: an overview. J Neurol (2008) 0.79
Specific immunotherapy: one size does not fit all. Nat Med (2000) 0.79
[Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology]. Nervenarzt (2011) 0.79
Evaluation of soluble HLA-G as a biomarker for multiple sclerosis. Neurology (2011) 0.79
Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult Scler (2009) 0.79
Localization of an encephalitogenic epitope for the SJL mouse in the N-terminal region of myelin basic protein. J Neuroimmunol (1990) 0.79
Intravenous thrombolysis in stroke patients with hyperdense middle cerebral artery sign. Eur J Neurol (2008) 0.78
[Revision of McDonald's new diagnostic criteria for multiple sclerosis]. Nervenarzt (2006) 0.78
[Multiple erythema migrans and facial nerve paralysis: clinical manifestations of early disseminated Lyme borreliosis]. Hautarzt (2014) 0.78
[Neurological aspects of systemic rheumatological disorders]. Z Rheumatol (2004) 0.77
[Myasthenia gravis: pathology, diagnosis and treatment]. Fortschr Neurol Psychiatr (2004) 0.77
Bacteria and their cell wall components uniformly co-activate interleukin-17-producing thymocytes. Clin Exp Immunol (2014) 0.77
[Blocking adhesion molecules with natalizumab in multiple sclerosis]. Nervenarzt (2005) 0.77
[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?]. Nervenarzt (2011) 0.77
Bioavailability of interferon-beta in patients with multiple sclerosis - fishing for the surrogate. Eur J Neurol (2009) 0.77
TACE mRNA expression in peripheral mononudear cells precedes new lesions on MRI in multiple sclerosis. Mult Scler (2002) 0.77
Peripheral blood levels of matrix metalloproteinase-9 predict lesion volume in acute stroke. Neurol Sci (2012) 0.77
[The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies]. Nervenarzt (2009) 0.77